Incorporating CGM into worksite health screenings may help employees gain insight into their glycemic patterns. This observational study piloted a voluntary health screening at a large employer that included 10 days of blinded Dexcom G6 CGM wear. At enrollment, HbA1c values and participants’ reports were used to assign diabetes status. Participants and their primary care providers received summaries of their CGM-based glucose profiles. A total of 207 participants (mean (sd) age = 50.7 (10), 84% female, 15% African American, 15% Hispanic, 56% obese) enrolled in the screening from April through August 2019, and 85% (175) wore the CGM for ≥4 days. HbA1c identified 7 and 24 participants with previously undiagnosed T2D and prediabetes, respectively. The final diabetes prevalence was 61 (35%) with T2D, 5 (3%) with T1D, 35 (20%) with prediabetes, and 74 (42%) with no diabetes. Among those with T2D, 27 (44%) met consensus-based goals for TIR. The Table shows CGM-based metrics from health screening participants compared to Shah’s (2019) normative sensor glucose data of people without diabetes. Those with prediabetes had higher mean glucose and lower TIR than the normative sample. Health screenings that include blinded CGM provide personalized feedback regarding glycemic patterns, even among people without known diabetes.


I.J. Klein: Consultant; Self; Dexcom, Inc. M. Crawford: Employee; Self; Dexcom, Inc. G.J. Norman: Employee; Self; Dexcom, Inc. K.C. Hames: Employee; Self; Dexcom, Inc. J.I. Justus: None. S. Treadwell: Employee; Self; Dexcom, Inc. T.M. Combee: None. S. Kinzler: Research Support; Self; Dexcom, Inc. J. Welsh: Employee; Self; CSL Behring. M. Johnson: Employee; Self; Dexcom, Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at